Comparative Pharmacology
Head-to-head clinical analysis: ENBREL versus HYRIMOZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENBREL versus HYRIMOZ.
ENBREL vs HYRIMOZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tumor necrosis factor (TNF) inhibitor; etanercept is a dimeric fusion protein consisting of the extracellular ligand-binding portion of human TNF receptor p75 linked to the Fc portion of human IgG1. It binds to soluble and membrane-bound TNF, thereby blocking TNF-mediated inflammatory responses.
HYRIMOZ (adalimumab-adbm) is a tumor necrosis factor (TNF) blocker. It binds to TNF-alpha and neutralizes its activity, thereby reducing inflammation and immune responses mediated by TNF.
50 mg subcutaneous injection once weekly
Subcutaneous injection: 40 mg every other week, or 80 mg every other week in patients with inadequate response. For induction in ulcerative colitis: 160 mg on day 1, 80 mg on day 15, then 40 mg every other week.
None Documented
None Documented
Approximately 102 hours (range 68–170 hours) after subcutaneous administration in adults; prolonged in elderly and patients with renal impairment; supports every 2-week dosing.
11-17 days (mean ~14 days). The long half-life supports subcutaneous every-other-week dosing with potential dose interval adjustment in patients with high body weight or if trough levels are subtherapeutic.
Renal: negligible; Biliary/Fecal: not significantly eliminated; primarily degraded via proteolysis into amino acids.
Predominantly catabolized to amino acids; renal excretion of metabolites and unchanged drug is negligible (<1%). Biliary/fecal excretion of intact antibody is minimal (<0.1%).
Category C
Category C
TNF-alpha Inhibitor
TNF-alpha Inhibitor